Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Vasculitis
•
Lupus nephritis
•
Cyclophosphamide
•
Scleroderma
•
SLE
When do you consider Mesna for patients taking oral cyclophosphamide?
What dose do you use? Do you utilize oral or IV infusion Mesna?
Related Questions
Should patients starting cyclophosphamide be screened routinely for latent tuberculosis (TB)?
What do you feel are the potential barriers to widespread use of obinutuzumab in proliferative lupus nephritis?
Do you hospitalize patients with newly diagnosed lupus nephritis and nephrotic syndrome if you are able to provide pulse steroids outpatient and follow them closely?
Should HCQ be continued in an asymptomatic SLE patient who has received renal transplant?
How soon after starting treatment for Takayasu arteritis do you decide on the need for any vascular interventions to manage chronic damage?
How do you approach the management of patients with moderate to high pre-test probabilty of GCA who are found to have negative findings on temporal artery biopsy?
What is your approach to nephrology referral for patients with lupus nephritis?
How do you approach management of a young adult after ascending thoracic aneurysm repair with biopsy showing granulomatous inflammation (no other vascular involvement, PET scan normal)?
Do you ever combine voclosporin and belimumab in the treatment of lupus nephritis?
How would you approach management of a patient with classic GCA symptoms, elevated ESR and improvement with steroids, but negative temporal artery biopsy and CTA imaging without evidence of vasculitis?